Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
GAITHERSBURG, Md., Aug. 01, 2017 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its second quarter financial and operating results following the close of U.S. financial markets on Tuesday, August 8, 2017.
Conference call details are as follows:
| Date: | Tuesday, August 8, 2017 |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) |
| Passcode: | 15614203 |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
Conference call and webcast replay:
| Dates: | Starts at 7:30 p.m. ET, August 8, 2017 until 7:30 pm ET, August 15, 2017 | |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | |
| Passcode: | 15614203 | |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until November 8, 2017 | |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Investor Relations Novavax, Inc. Andrea N. Flynn, Ph.D. Director, Investor Relations [email protected] 240-268-2000 Westwicke Partners John Woolford [email protected] 443-213-0506 Media Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] 212-845-4271
